OverviewSuggest Edit

QGel’s synthetic and tunable extracellular matrix (ECM) technology mimics the complex physiology of the human body, enabling the growth of any human or animal tissue in vitro. QGel enables drug development in a laboratory environment that accurately and reliably mimics the functioning of human organs, which means greater predictability of drug efficacy before the clinical phase. With an improved understanding of a drug’s potential, researchers spend more time and resources on the most promising therapies.
TypePrivate
Founded2009
HQYvorne, CH
Websiteqgelbio.com

Latest Updates

Employees (est.) (Oct 2019)15

Key People/Management at QGel

Colin Sanctuary

Colin Sanctuary

Chief Executive Officer, Board Member & Founder
Matthias Lutolf

Matthias Lutolf

Co-Founder
Show more

QGel Office Locations

QGel has an office in Yvorne
Yvorne, CH (HQ)
1015 Route de Lausanne
Show all (1)

QGel Financials and Metrics

Summary Metrics

Founding Date

2009

QGel total Funding

$12 m

QGel latest funding size

$12 m

Time since last funding

3 years ago
QGel's latest funding round in December 2016 was reported to be $12 m. In total, QGel has raised $12 m
Show all financial metrics

QGel Online and Social Media Presence

Embed Graph

QGel Blogs

Growing mini tumours to predict drug response

                  Click image to watch video

Swiss Startup QGel Commercializing 3D Organoids for Cancer Drug Response Research

by John Gilmore Original Article: www.genomeweb.com Swiss startup QGel has developed a series of synthetic extracellular matrices (ECMs) based on […]

Scientists Grow Head and Neck Cancer Organoids to Personalize Chemotherapy

Head and neck cancer is an aggressive disease that often requires harsh chemotherapy and radiotherapy to treat. It is possible […]

Cancer modeling meets human organoid technology

Abstract Organoids are microscopic self-organizing, three-dimensional structures that are grown from stem cells in vitro. They recapitulate many structural and […]

Organoids: bringing life to precision medicine

Swiss-based biotech QGel is hoping to offer a novel approach to precision medicine by solving several of the current challenges […]

QGel wins two separate global innovation awards from Fast Company and the Edison Awards

QGel has been awarded two prizes recognizing innovation and world changing ideas. On April 8, 2019, QGel was selected as […]
Show more

QGel Frequently Asked Questions

  • When was QGel founded?

    QGel was founded in 2009.

  • Who are QGel key executives?

    QGel's key executives are Colin Sanctuary and Matthias Lutolf.

  • How many employees does QGel have?

    QGel has 15 employees.

  • Who are QGel competitors?

    Competitors of QGel include Pierrel, Nuvaira and Microbion.

  • Where is QGel headquarters?

    QGel headquarters is located at 1015 Route de Lausanne, Yvorne.

  • Where are QGel offices?

    QGel has an office in Yvorne.

  • How many offices does QGel have?

    QGel has 1 office.